Remove how-to-patent-in-china
article thumbnail

How to Patent in China

Patent Trademark Blog

Does it make sense to get a patent in China? One of the most frequent questions I get about getting a patent in China is whether anyone should even bother. Why file a patent overseas when you cannot enforce it? Keep in mind that I am a US patent attorney. Need to file a patent in China?

Patent 98
article thumbnail

Hytera Sanctions Show Strength Of Antisuit Injunctions

IP Law 360

The Seventh Circuit's decision upholding $1 million a day in sanctions against Hytera Communications for violating an order to drop trade secrets and copyright litigation in China highlights the difficulty for lawyers when working alongside Chinese courts, while affirming to patent attorneys how powerful antisuit injunctions can be.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2023-2024

LexBlog IP

The BPCIA also introduced a new scheme to resolve patent disputes involving biosimilar products known as the “patent dance.” ” Since the enactment of the BPCIA, the FDA has approved 46 biosimilar products, and, as the market has grown, litigation activity concerning biosimilars has increased rapidly.

article thumbnail

New Developments in China Trade Secret Litigation

LexBlog IP

New Developments in China Trade Secret Litigation by Founders Legal China’s Growing Focus on Intellectual Property: The Beijing IP Court Steps Up Protections Trade secrets have become increasingly important in today’s globalized business environment, serving as vital intangible assets for many companies.

article thumbnail

Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021

LexBlog IP

The BPCIA also introduced a new scheme to resolve patent disputes involving biosimilar products known as the “patent dance.” ” Since the enactment of the BPCIA, the FDA has approved nearly 30 biosimilar products, and, as the market has grown, litigation activity concerning biosimilars has increased rapidly.

article thumbnail

Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023

LexBlog IP

The BPCIA also introduced a new scheme to resolve patent disputes involving biosimilar products known as the “patent dance.” ” Since the enactment of the BPCIA, the FDA has approved 40 biosimilar products, and, as the market has grown, litigation activity concerning biosimilars has increased rapidly.

article thumbnail

Kurt Glitzenstein Quoted in The American Lawyer “Litigation Leaders” Article

Fish & Richardson Trademark & Copyright Thoughts

Fish attorney Kurt Glitzenstein spoke with The American Lawyer about Fish’s success on being the busiest patent litigation firm in the land. He discusses his goals and priorities as the Litigation Practice Group leader, where the firm is looking to expand in the next year, and more. I received my B.S. I received my B.S.